Market Cap | 4.70M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
Income | -9.25M | Forward P/E | -0.27 | EPS next Y | - | 50D Avg Chg | -76.00% |
Sales | 5.64M | PEG | - | EPS past 5Y | - | 200D Avg Chg | -87.00% |
Dividend | N/A | Price/Book | 0.44 | EPS next 5Y | 472.00% | 52W High Chg | -96.00% |
Recommedations | 3.00 | Quick Ratio | 3.49 | Shares Outstanding | 12.23M | 52W Low Chg | 15.00% |
Insider Own | 15.03% | ROA | -78.47% | Shares Float | 10.20M | Beta | 0.68 |
Inst Own | 10.39% | ROE | -165.96% | Shares Shorted/Prior | 90.45K/123.63K | Price | 0.45 |
Gross Margin | 100.00% | Profit Margin | -164.06% | Avg. Volume | 607,854 | Target Price | - |
Oper. Margin | -195.76% | Earnings Date | Apr 25 | Volume | 74,899 | Change | 0.85% |
Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse, which is in Phase 3 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; which has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that has completed Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension and pulmonary hypertension associated with pulmonary edema from high altitude sickness. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.
HC Wainwright & Co. | Buy | Jun 6, 23 |
Laidlaw & Co. | Hold | Jun 6, 23 |
Laidlaw & Co. | Buy | May 9, 23 |
HC Wainwright & Co. | Buy | Apr 4, 23 |
Jefferies | Buy | Aug 11, 20 |
Maxim Group | Buy | Jan 24, 19 |
HC Wainwright & Co. | Buy | Jan 20, 17 |
Leerink Swann | Outperform | Mar 16, 15 |
SunTrust Robinson Humphrey | Buy | Mar 16, 15 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Puissance Capital Management L... | 10% Owner 10% Owner | Oct 13 | Sell | 0.1038 | 1,076,841 | 111,776 | 10/16/23 | |
Puissance Life Science Opportu... | 10% Owner 10% Owner | Jun 07 | Sell | 0.83 | 134,421 | 111,569 | 1,076,841 | 06/07/23 |
Kim Bobae | VP Reg. Affairs & Qu.. VP Reg. Affairs & Quality | May 18 | Sell | 10 | 9,455 | 94,550 | 1,723 | 05/22/23 |
Kim Bobae | VP Reg. Affairs & Qu.. VP Reg. Affairs & Quality | May 18 | Option | 7.43 | 1,288 | 9,570 | 1,723 | 05/22/23 |
Puissance Life Science Opportu... | 10% Owner 10% Owner | May 18 | Sell | 9.46 | 560,000 | 5,297,600 | 1,211,262 | 05/19/23 |